請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47067
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林琬琬 | |
dc.contributor.author | Yeo-Loo Chang | en |
dc.contributor.author | 張佑如 | zh_TW |
dc.date.accessioned | 2021-06-15T05:46:41Z | - |
dc.date.available | 2015-09-13 | |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-19 | |
dc.identifier.citation | Abbracchio, M.P., and Burnstock, G. (1998). Purinergic signalling: pathophysiological roles. Jpn J Pharmacol 78, 113-145.
Aggarwal, B.B., Vijayalekshmi, R.V., and Sung, B. (2009). Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15, 425-430. Aries, A., Paradis, P., Lefebvre, C., Schwartz, R.J., and Nemer, M. (2004). Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A 101, 6975-6980. Arlt, A., Vorndamm, J., Breitenbroich, M., Folsch, U.R., Kalthoff, H., Schmidt, W.E., and Schafer, H. (2001). Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20, 859-868. Bachur, N.R., Gordon, S.L., and Gee, M.V. (1977). Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 13, 901-910. Bachur, N.R., Johnson, R., Yu, F., Hickey, R., Applegren, N., and Malkas, L. (1993). Antihelicase action of DNA-binding anticancer agents: relationship to guanosine-cytidine intercalator binding. Mol Pharmacol 44, 1064-1069. Bachur, N.R., Lun, L., Sun, P.M., Trubey, C.M., Elliott, E.E., Egorin, M.J., Malkas, L., and Hickey, R. (1998). Anthracycline antibiotic blockade of SV40 T antigen helicase action. Biochem Pharmacol 55, 1025-1034. Bates, D.A., and Winterbourn, C.C. (1982). Deoxyribose breakdown by the adriamycin semiquinone and H2O2: evidence for hydroxyl radical participation. FEBS Lett 145, 137-142. Bernuzzi, F., Recalcati, S., Alberghini, A., and Cairo, G. (2009). Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 down-modulation. Chem Biol Interact 177, 12-20. Blum, R.H., and Carter, S.K. (1974). Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80, 249-259. Boucek, R.J., Jr., Miracle, A., Anderson, M., Engelman, R., Atkinson, J., and Dodd, D.A. (1999). Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol 31, 1435-1446. Brooks, C.L., and Gu, W. (2006). p53 ubiquitination: Mdm2 and beyond. Mol Cell 21, 307-315. Brown, C.J., Lain, S., Verma, C.S., Fersht, A.R., and Lane, D.P. (2009). Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9, 862-873. Burnstock, G., and Knight, G.E. (2004). Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240, 31-304. Bustamante, J., Galleano, M., Medrano, E.E., and Boveris, A. (1990). Adriamycin effects on hydroperoxide metabolism and growth of human breast tumor cells. Breast Cancer Res Treat 17, 145-153. Chang, C.C., Shih, J.Y., Jeng, Y.M., Su, J.L., Lin, B.Z., Chen, S.T., Chau, Y.P., Yang, P.C., and Kuo, M.L. (2004). Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 96, 364-375. Chang, Y.W., Chen, S.C., Cheng, E.C., Ko, Y.P., Lin, Y.C., Kao, Y.R., Tsay, Y.G., Yang, P.C., Wu, C.W., and Roffler, S.R. (2005). CD13 (aminopeptidase N) can associate with tumor-associated antigen L6 and enhance the motility of human lung cancer cells. Int J Cancer 116, 243-252. Chen, J.J., Peck, K., Hong, T.M., Yang, S.C., Sher, Y.P., Shih, J.Y., Wu, R., Cheng, J.L., Roffler, S.R., Wu, C.W., and Yang, P.C. (2001). Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 61, 5223-5230. Childs, A.C., Phaneuf, S.L., Dirks, A.J., Phillips, T., and Leeuwenburgh, C. (2002). Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 62, 4592-4598. Chu, Y.W., Yang, P.C., Yang, S.C., Shyu, Y.C., Hendrix, M.J., Wu, R., and Wu, C.W. (1997). Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 17, 353-360. Chuang, L.F., Chuang, R.Y., Acton, E.M., Israel, M., and Yu, M. (1987). Effect of morpholinyladriamycin analogs and adriamycin on the activities of DNA polymerase alpha and RNA polymerase II of chicken leukemia cells. J Pharmacol Exp Ther 242, 372-377. Cullinane, C., and Phillips, D.R. (1990). Induction of stable transcriptional blockage sites by adriamycin: GpC specificity of apparent adriamycin-DNA adducts and dependence on iron(III) ions. Biochemistry 29, 5638-5646. Cutts, S.M., Nudelman, A., Rephaeli, A., and Phillips, D.R. (2005). The power and potential of doxorubicin-DNA adducts. IUBMB Life 57, 73-81. Cutts, S.M., Parker, B.S., Swift, L.P., Kimura, K.I., and Phillips, D.R. (2000). Structural requirements for the formation of anthracycline-DNA adducts. Anticancer Drug Des 15, 373-386. Dal Ben, D., Palumbo, M., Zagotto, G., Capranico, G., and Moro, S. (2007). DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation. Curr Pharm Des 13, 2766-2780. De Visser, K.E., Eichten, A., and Coussens, L.M. (2006). Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6, 24-37. DeAtley, S.M., Aksenov, M.Y., Aksenova, M.V., Carney, J.M., and Butterfield, D.A. (1998). Adriamycin induces protein oxidation in erythrocyte membranes. Pharmacol Toxicol 83, 62-68. Deffie, A.M., Batra, J.K., and Goldenberg, G.J. (1989). Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49, 58-62. Dunn, G.P., Old, L.J., and Schreiber, R.D. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148. Eguchi, Y., Shimizu, S., and Tsujimoto, Y. (1997). Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 57, 1835-1840. Eliot, H., Gianni, L., and Myers, C. (1984). Oxidative destruction of DNA by the adriamycin-iron complex. Biochemistry 23, 928-936. Erdmann, A.A., Gao, Z.G., Jung, U., Foley, J., Borenstein, T., Jacobson, K.A., and Fowler, D.H. (2005). Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 105, 4707-4714. Feinstein, E., Canaani, E., and Weiner, L.M. (1993). Dependence of nucleic acid degradation on in situ free-radical production by adriamycin. Biochemistry 32, 13156-13161. Feoktistov, I., Goldstein, A.E., Ryzhov, S., Zeng, D., Belardinelli, L., Voyno-Yasenetskaya, T., and Biaggioni, I. (2002). Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res 90, 531-538. Ferrans, V.J. (1978). Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62, 955-961. Fisher, J., Abdella, B.R., and McLane, K.E. (1985). Anthracycline antibiotic reduction by spinach ferredoxin-NADP+ reductase and ferredoxin. Biochemistry 24, 3562-3571. Friche, E., Danks, M.K., Schmidt, C.A., and Beck, W.T. (1991). Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res 51, 4213-4218. Friesen, C., Fulda, S., and Debatin, K.M. (1999). Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ 6, 471-480. Gamen, S., Anel, A., Perez-Galan, P., Lasierra, P., Johnson, D., Pineiro, A., and Naval, J. (2000). Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res 258, 223-235. Gangadharan, C., Thoh, M., and Manna, S.K. (2009). Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis. J Cell Biochem 107, 203-213. Gangadharan, C., Thoh, M., and Manna, S.K. (2010). Late phase activation of nuclear transcription factor kappaB by doxorubicin is mediated by interleukin-8 and induction of apoptosis via FasL. Breast Cancer Res Treat 120, 671-683. Gao, M., Yeh, P.Y., Lu, Y.S., Chang, W.C., Kuo, M.L., and Cheng, A.L. (2008). NF-kappaB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells. Biochem Biophys Res Commun 376, 283-287. Gessi, S., Cattabriga, E., Avitabile, A., Gafa, R., Lanza, G., Cavazzini, L., Bianchi, N., Gambari, R., Feo, C., Liboni, A., Gullini, S., Leung, E., Mac-Lennan, S., and Borea, P.A. (2004). Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 10, 5895-5901. Gewirtz, D.A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57, 727-741. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., Perfettini, J.L., Schlemmer, F., Tasdemir, E., Uhl, M., Genin, P., Civas, A., Ryffel, B., Kanellopoulos, J., Tschopp, J., Andre, F., Lidereau, R., McLaughlin, N.M., Haynes, N.M., Smyth, M.J., Kroemer, G., and Zitvogel, L. (2009). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15, 1170-1178. Goodman, M.F., and Lee, G.M. (1977). Adriamycin interactions with T4 DNA polymerase. Two modes of template-mediated inhibition. J Biol Chem 252, 2670-2674. Green, D.R., and Kroemer, G. (2009). Cytoplasmic functions of the tumour suppressor p53. Nature 458, 1127-1130. Green, P.S., and Leeuwenburgh, C. (2002). Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta 1588, 94-101. Grivennikov, S.I., Greten, F.R., and Karin, M. (2010). Immunity, inflammation, and cancer. Cell 140, 883-899. Gutteridge, J.M., and Quinlan, G.J. (1985). Free radical damage to deoxyribose by anthracycline, aureolic acid and aminoquinone antitumour antibiotics. An essential requirement for iron, semiquinones and hydrogen peroxide. Biochem Pharmacol 34, 4099-4103. Hatta, Y., Takahashi, M., Enomoto, Y., Takahashi, N., Sawada, U., and Horie, T. (2004). Adenosine triphosphate (ATP) enhances the antitumor effect of etoposide (VP16) in lung cancer cells. Oncol Rep 12, 1139-1142. Ho, C.C., Huang, P.H., Huang, H.Y., Chen, Y.H., Yang, P.C., and Hsu, S.M. (2002). Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 161, 1647-1656. Honda, R., and Yasuda, H. (1999). Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18, 22-27. Kalivendi, S.V., Konorev, E.A., Cunningham, S., Vanamala, S.K., Kaji, E.H., Joseph, J., and Kalyanaraman, B. (2005). Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. Biochem J 389, 527-539. Kao, Y.R., Shih, J.Y., Wen, W.C., Ko, Y.P., Chen, B.M., Chan, Y.L., Chu, Y.W., Yang, P.C., Wu, C.W., and Roffler, S.R. (2003). Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res 9, 2807-2816. Kappus, H. (1986). Overview of enzyme systems involved in bio-reduction of drugs and in redox cycling. Biochem Pharmacol 35, 1-6. Kim, H.S., Lee, Y.S., and Kim, D.K. (2009). Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death. Pharmacology 84, 300-309. Kim, S.Y., Kim, S.J., Kim, B.J., Rah, S.Y., Chung, S.M., Im, M.J., and Kim, U.H. (2006). Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med 38, 535-545. Kim, Y., Ma, A.G., Kitta, K., Fitch, S.N., Ikeda, T., Ihara, Y., Simon, A.R., Evans, T., and Suzuki, Y.J. (2003). Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 63, 368-377. Kurz, E.U., Douglas, P., and Lees-Miller, S.P. (2004). Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 279, 53272-53281. L'Ecuyer, T., Sanjeev, S., Thomas, R., Novak, R., Das, L., Campbell, W., and Heide, R.V. (2006). DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 291, H1273-1280. Lebrecht, D., Kokkori, A., Ketelsen, U.P., Setzer, B., and Walker, U.A. (2005). Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol 207, 436-444. Leist, M., Single, B., Castoldi, A.F., Kuhnle, S., and Nicotera, P. (1997). Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 185, 1481-1486. Lin, W.W., and Karin, M. (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117, 1175-1183. Linares, L.K., Hengstermann, A., Ciechanover, A., Muller, S., and Scheffner, M. (2003). HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A 100, 12009-12014. Liu, J., Mao, W., Ding, B., and Liang, C.S. (2008). ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 295, H1956-1965. Liu, L.F., Rowe, T.C., Yang, L., Tewey, K.M., and Chen, G.L. (1983). Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258, 15365-15370. Liu, X., Chua, C.C., Gao, J., Chen, Z., Landy, C.L., Hamdy, R., and Chua, B.H. (2004). Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice. Am J Physiol Heart Circ Physiol 286, H933-939. Lorenzo, E., Ruiz-Ruiz, C., Quesada, A.J., Hernandez, G., Rodriguez, A., Lopez-Rivas, A., and Redondo, J.M. (2002). Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 277, 10883-10892. Madi, L., Ochaion, A., Rath-Wolfson, L., Bar-Yehuda, S., Erlanger, A., Ohana, G., Harish, A., Merimski, O., Barer, F., and Fishman, P. (2004). The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 10, 4472-4479. Marco, A., and Arcamone, F. (1975). DNA complexing antibiotics: daunomycin, adriamycin and their derivatives. Arzneimittelforschung 25, 368-374. Marine, J.C., and Jochemsen, A.G. (2004). Mdmx and Mdm2: brothers in arms? Cell Cycle 3, 900-904. Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Seror, C., Metivier, D., Perfettini, J.L., Zitvogel, L., and Kroemer, G. (2009). Chemotherapy induces ATP release from tumor cells. Cell Cycle 8, 3723-3728. Massart, C., Barbet, R., Genetet, N., and Gibassier, J. (2004). Doxorubicin induces Fas-mediated apoptosis in human thyroid carcinoma cells. Thyroid 14, 263-270. Merighi, S., Mirandola, P., Milani, D., Varani, K., Gessi, S., Klotz, K.N., Leung, E., Baraldi, P.G., and Borea, P.A. (2002). Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 119, 923-933. Meulmeester, E., Maurice, M.M., Boutell, C., Teunisse, A.F., Ovaa, H., Abraham, T.E., Dirks, R.W., and Jochemsen, A.G. (2005a). Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 18, 565-576. Meulmeester, E., Pereg, Y., Shiloh, Y., and Jochemsen, A.G. (2005b). ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle 4, 1166-1170. Mimnaugh, E.G., Trush, M.A., Bhatnagar, M., and Gram, T.E. (1985). Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem Pharmacol 34, 847-856. Mizutani, H., Tada-Oikawa, S., Hiraku, Y., Kojima, M., and Kawanishi, S. (2005). Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 76, 1439-1453. Momand, J., Zambetti, G.P., Olson, D.C., George, D., and Levine, A.J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245. Momparler, R.L., Karon, M., Siegel, S.E., and Avila, F. (1976). Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 36, 2891-2895. Moore, H.W. (1977). Bioactivation as a model for drug design bioreductive alkylation. Science 197, 527-532. Moro, S., Beretta, G.L., Dal Ben, D., Nitiss, J., Palumbo, M., and Capranico, G. (2004). Interaction model for anthracycline activity against DNA topoisomerase II. Biochemistry 43, 7503-7513. Muindi, J.R., Sinha, B.K., Gianni, L., and Myers, C.E. (1984). Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. FEBS Lett 172, 226-230. Mukhopadhyay, P., Rajesh, M., Batkai, S., Kashiwaya, Y., Hasko, G., Liaudet, L., Szabo, C., and Pacher, P. (2009). Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 296, H1466-1483. Myers, C.E., McGuire, W.P., Liss, R.H., Ifrim, I., Grotzinger, K., and Young, R.C. (1977). Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197, 165-167. Nicotera, P., Leist, M., and Ferrando-May, E. (1998). Intracellular ATP, a switch in the decision between apoptosis and necrosis. Toxicol Lett 102-103, 139-142. Ohta, A., Gorelik, E., Prasad, S.J., Ronchese, F., Lukashev, D., Wong, M.K., Huang, X., Caldwell, S., Liu, K., Smith, P., Chen, J.F., Jackson, E.K., Apasov, S., Abrams, S., and Sitkovsky, M. (2006). A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 103, 13132-13137. Panaretakis, T., Pokrovskaja, K., Shoshan, M.C., and Grander, D. (2002). Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 277, 44317-44326. Park, S.S., Kim, M.A., Eom, Y.W., and Choi, K.S. (2007). Bcl-xL blocks high dose doxorubicin-induced apoptosis but not low dose doxorubicin-induced cell death through mitotic catastrophe. Biochem Biophys Res Commun 363, 1044-1049. Parra, V., Eisner, V., Chiong, M., Criollo, A., Moraga, F., Garcia, A., Hartel, S., Jaimovich, E., Zorzano, A., Hidalgo, C., and Lavandero, S. (2008). Changes in mitochondrial dynamics during ceramide-induced cardiomyocyte early apoptosis. Cardiovasc Res 77, 387-397. Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., and Di Virgilio, F. (2008). Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 3, e2599. Phillips, D.R., White, R.J., and Cullinane, C. (1989). DNA sequence-specific adducts of adriamycin and mitomycin C. FEBS Lett 246, 233-240. Picksley, S.M., and Lane, D.P. (1993). The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15, 689-690. Portugal, J., Martin, B., Vaquero, A., Ferrer, N., Villamarin, S., and Priebe, W. (2001). Analysis of the effects of daunorubicin and WP631 on transcription. Curr Med Chem 8, 1-8. Rabbani, A., Finn, R.M., Thambirajah, A.A., and Ausio, J. (2004). Binding of antitumor antibiotic daunomycin to histones in chromatin and in solution. Biochemistry 43, 16497-16504. Ralevic, V., and Burnstock, G. (1998). Receptors for purines and pyrimidines. Pharmacol Rev 50, 413-492. Ramakrishnan, K., and Fisher, J. (1986). 7-Deoxydaunomycinone quinone methide reactivity with thiol nucleophiles. J Med Chem 29, 1215-1221. Ravi, D., Muniyappa, H., and Das, K.C. (2005). Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. J Biol Chem 280, 40084-40096. Sardao, V.A., Oliveira, P.J., Holy, J., Oliveira, C.R., and Wallace, K.B. (2009). Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemother Pharmacol 64, 811-827. Schafer, R., Hartig, R., Sedehizade, F., Welte, T., and Reiser, G. (2006). Adenine nucleotides inhibit proliferation of the human lung adenocarcinoma cell line LXF-289 by activation of nuclear factor kappaB1 and mitogen-activated protein kinase pathways. FEBS J 273, 3756-3767. Schafer, R., Sedehizade, F., Welte, T., and Reiser, G. (2003). ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. Am J Physiol Lung Cell Mol Physiol 285, L376-385. Schreiber, V., Dantzer, F., Ame, J.C., and de Murcia, G. (2006). Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7, 517-528. Shih, J.Y., Yang, S.C., Hong, T.M., Yuan, A., Chen, J.J., Yu, C.J., Chang, Y.L., Lee, Y.C., Peck, K., Wu, C.W., and Yang, P.C. (2001). Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst 93, 1392-1400. Sinha, B.K., Trush, M.A., Kennedy, K.A., and Mimnaugh, E.G. (1984). Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Res 44, 2892-2896. Skladanowski, A., and Konopa, J. (1994). Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity. Biochem Pharmacol 47, 2279-2287. Solem, L.E., Henry, T.R., and Wallace, K.B. (1994). Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol Appl Pharmacol 129, 214-222. Stommel, J.M., and Wahl, G.M. (2004). Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 23, 1547-1556. Studzian, K., Wasowska, M., Piestrzeniewicz, M.K., Wilmanska, D., Szmigiero, L., Oszczapowicz, I., and Gniazdowski, M. (2001). Inhibition of RNA synthesis in vitro and cell growth by anthracycline antibiotics. Neoplasma 48, 412-418. Swennen, E.L., Ummels, V., Buss, I., Jaehde, U., Bast, A., and Dagnelie, P.C. (2010). ATP sensitizes H460 lung carcinoma cells to cisplatin-induced apoptosis. Chem Biol Interact 184, 338-345. Synowitz, M., Glass, R., Farber, K., Markovic, D., Kronenberg, G., Herrmann, K., Schnermann, J., Nolte, C., van Rooijen, N., Kiwit, J., and Kettenmann, H. (2006). A1 adenosine receptors in microglia control glioblastoma-host interaction. Cancer Res 66, 8550-8557. Tang, Y., Zhao, W., Chen, Y., Zhao, Y., and Gu, W. (2008). Acetylation is indispensable for p53 activation. Cell 133, 612-626. Tewey, K.M., Chen, G.L., Nelson, E.M., and Liu, L.F. (1984a). Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259, 9182-9187. Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D., and Liu, L.F. (1984b). Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226, 466-468. Tian, T., Hao, J., Xu, A., Luo, C., Liu, C., Huang, L., Xiao, X., and He, D. (2007). Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci 98, 1265-1274. Travis, W.D., Travis, L.B., and Devesa, S.S. (1995). Lung cancer. Cancer 75, 191-202. Tuteja, N., Phan, T.N., Tuteja, R., Ochem, A., and Falaschi, A. (1997). Inhibition of DNA unwinding and ATPase activities of human DNA helicase II by chemotherapeutic agents. Biochem Biophys Res Commun 236, 636-640. Wang, S., Kotamraju, S., Konorev, E., Kalivendi, S., Joseph, J., and Kalyanaraman, B. (2002). Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J 367, 729-740. Webb, C.D., Latham, M.D., Lock, R.B., and Sullivan, D.M. (1991). Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51, 6543-6549. Whibley, C., Pharoah, P.D., and Hollstein, M. (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer 9, 95-107. Wu, H.Y., Tseng, V.S., Chen, L.C., Chang, H.Y., Chuang, I.C., Tsay, Y.G., and Liao, P.C. (2010). Identification of Tyrosine-Phosphorylated Proteins Associated with Lung Cancer Metastasis using Label-Free Quantitative Analyses. J Proteome Res. Yamaoka, M., Yamaguchi, S., Suzuki, T., Okuyama, M., Nitobe, J., Nakamura, N., Mitsui, Y., and Tomoike, H. (2000). Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. J Mol Cell Cardiol 32, 881-889. Yeh, P.Y., Chuang, S.E., Yeh, K.H., Song, Y.C., Chang, L.L., and Cheng, A.L. (2004). Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 23, 3580-3588. Zarek, P.E., Huang, C.T., Lutz, E.R., Kowalski, J., Horton, M.R., Linden, J., Drake, C.G., and Powell, J.D. (2008). A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111, 251-259. Zhou, S., Starkov, A., Froberg, M.K., Leino, R.L., and Wallace, K.B. (2001). Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 61, 771-777. Zhu, W., Soonpaa, M.H., Chen, H., Shen, W., Payne, R.M., Liechty, E.A., Caldwell, R.L., Shou, W., and Field, L.J. (2009). Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119, 99-106. Zunino, F., Gambetta, R., Di Marco, A., and Zaccara, A. (1972). Interaction of daunomycin and its derivatives with DNA. Biochim Biophys Acta 277, 489-498. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47067 | - |
dc.description.abstract | 此實驗中,我們探討三磷酸腺苷(ATP)對於doxorubicin在二株肺癌細胞CL1.0及CL1.5的細胞毒性之影響。這兩株肺癌細胞株的最大不同點是CL1.5相較於CL1.0是具有高度轉移能力及抗藥性。我們利用doxorubicin測試細胞毒性證實CL1.0的確對doxorubicin有高敏感性。但不論對doxorubicin的敏感性為何,外給ATP均會抑制doxorubicin對CL1.0及CL1.5所引發的細胞死亡。實驗結果顯示ATP會減弱doxorubicin對於CL1.0細胞所造成的細胞凋亡及細胞壞死現象,如會抑制sub-G1 peak的產生、caspase 3 的活化、propidium iodide 的吸收、及活性氧化物的產生。此外ATP亦可抑制doxorubicin所誘發的p53累積及活化。同時給予p53抑制劑pifithrin-α時會抑制doxorubicin的毒性,而此情況下ATP的保護細胞效果降低,顯示p53在ATP的保護作用中扮演一個重要的角色。同時,活性氧化物清除者(ROS scavenger) N-acetylcysteine亦可保護doxorubicin引起的細胞死亡、p53的累積及PAR的產生。此外,我們發現在同時給予ATP的情況下,相較於只有doxorubicin處理的組別,會更增加NF-κB的活性。其他嘌呤核苷酸,例如UTP,UDP及ADP也會抑制doxorubicin的抗腫瘤活性。然而,ATP不會保護其他具有細胞毒性的藥物所造成的細胞死亡,且ATP保護CL1.0細胞的作用在其他的癌細胞,如PC3及HeLa細胞中是看不到的。總括而言,雖然doxorubicin在CL1.0及CL1.5兩株細胞有不同的敏感性,但ATP同樣具有對抗其細胞毒性的作用。降低活性氧化物的產生、DNA的傷害、p53及caspase 3活化,及促進NF-κB活化均貢獻於ATP保護肺癌細胞株免受doxorubicin的毒殺作用。 | zh_TW |
dc.description.abstract | In the present study, we investigated the effect of ATP on the cytotoxicity of doxorubicin in two lung cancer cell lines, CL1.0 and CL1.5. The major difference of both cell lines is that CL1.0 is nonmetastatic, while CL1.5 is highly metastatic. Here, we confirmed that CL1.5 cells are more resistant to doxorubicin (DXR) as compared to CL1.0 cells, and found exogenous ATP can protect DXR-induced cell death in both cell lines. Both apoptosis (characterized by sub-G1 peak, caspase 3 activation) and necrosis (characterized by propidium iodide uptake and ROS production) features induced by DXR in CL1.0 were reduced by ATP. In addition, ATP can inhibit p53 accumulation and phosphorylation under DXR treatment. The cytotoxicity of DXR was diminished by the treatment with p53 inhibitor pifithrin-α, indicating the role of p53 in the anti-tumor action of DXR. Moreover, ROS scavenger N-acetylcysteine protected cell death, p53 accumulation and PAR formation induced by DXR. Besides, we found that combination treatment with ATP enhanced more NF-κB activation compared to DXR treatment alone. Other purinergic nucleotides, such as UTP, UDP and ADP, also diminished the antitumor activity of DXR in CL1.0. However, we found such cytoprotective effect of ATP was neither observed for other cytotoxic agents in CL1.0 cells or even for DXR action in PC3 prostate and HeLa cervical cancer cell lines. In summary, even though DXR has differential anti-tumor sensitivity in CL1.0 and CL1.5 lung cancer cells, ATP can protect both cell lines against DXR-induced cell death. Attenuation of ROS production, DNA damage, p53 and caspase activation, as well as the increase in NF-κB activation might all contribute to the cytoprotective effect of ATP on DXR-induced mixed type of cell death in CL1.0. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T05:46:41Z (GMT). No. of bitstreams: 1 ntu-99-R97443003-1.pdf: 1580448 bytes, checksum: d80f6f115210c78e52a065d41c3e13de (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | Abbreviations……………………………………………………2
Abstract…………………………………………………………3 中文摘要..………………………………………………………5 Introduction……………………………………………………7 Materials and Methods…………………………………………20 Results………………………………………………….………29 Discussion……………………………………………………36 Figures…………………………………………………………42 Appendix ………………………………………………………58 References…………………………………………..………62 | |
dc.language.iso | en | |
dc.title | 三磷酸腺苷對於Doxorubicin的抗腫瘤活性之調節 | zh_TW |
dc.title | Modulatory effect of ATP on doxorubicin-mediated antitumor activity | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 顏茂雄,符文美,陳炳常 | |
dc.subject.keyword | 三磷酸腺苷,肺癌, | zh_TW |
dc.subject.keyword | ATP,Doxorubicin,lung cancer, | en |
dc.relation.page | 71 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-19 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 1.54 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。